Flamingo Therapeutics is pioneering RNA-targeted therapies for oncology.
Flamingo Therapeutics has raised $1.9M in total funding. The most recent round was Grant. The last funding was announced in June 2023.
Flamingo Therapeutics's investors include Agentschap Innoveren & Ondernemen.
Flamingo Therapeutics is headquartered in Leuven, Belgium.
Flamingo Therapeutics is pioneering RNA-targeted therapies for oncology.
Flamingo Therapeutics is at the Grant stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Flamingo Therapeutics — Funding & Investors." VCBacked, June 15, 2023, https://www.vcbacked.co/company/flamingo-therapeutics. Accessed September 30, 2026.
VCBacked. (2023). Flamingo Therapeutics — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/flamingo-therapeutics
{{cite web |title=Flamingo Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/flamingo-therapeutics |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated